Concerning the candidate genes identified as potential molecular biomarkers for rectal cancer, GFRA1, and GSTM2, aberrant methylation of GSTM2 has previously been identified in prostate cancer, breast cancer and oral squamous cell carcinoma [29, 42, 43]. This evidence concerns the gene GFRA1 and rectal cancer.